| Auburn Surgery Center Inc. | |
|
300 S Mount Auburn Rd Ste 200 Cape Girardeau MO 63703-4920 | |
| (573) 651-4488 | |
| (573) 651-4432 |
| Full Name | Auburn Surgery Center Inc. |
|---|---|
| Speciality | Clinic/Center |
| Location | 300 S Mount Auburn Rd, Cape Girardeau, Missouri |
| Authorized Official Name and Position | Gregory A Tobin (PRESIDENT) |
| Authorized Official Contact | 5736514488 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Auburn Surgery Center Inc. Po Box 70 Cape Girardeau MO 63702-0070 Ph: (573) 332-7881 | Auburn Surgery Center Inc. 300 S Mount Auburn Rd Ste 200 Cape Girardeau MO 63703-4920 Ph: (573) 651-4488 |
| NPI Number | 1265431670 |
|---|---|
| Provider Enumeration Date | 07/18/2005 |
| Last Update Date | 09/22/2017 |
| Medicare PECOS PAC ID | 2961567854 |
|---|---|
| Medicare Enrollment ID | O20090209000625 |
News Archive
Metabolic syndrome in children represents a potentially serious threat to health in adulthood, yet many parents and caregivers do not have a clear idea of what metabolic syndrome is and why it is dangerous.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company's 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.
Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265431670 | NPI | - | NPPES |
| 503861502 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | 113.2 (Missouri) | Secondary |
| 261QA1903X | Clinic/center - Ambulatory Surgical | (* (Not Available)) | Primary |
| Provider Name | Charles H. Goshen |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1750593927 PECOS PAC ID: 6901852581 Enrollment ID: I20051117000570 |
News Archive
Metabolic syndrome in children represents a potentially serious threat to health in adulthood, yet many parents and caregivers do not have a clear idea of what metabolic syndrome is and why it is dangerous.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company's 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.
Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.
› Verified 3 days ago
| Provider Name | Tressa H Neely |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1568603355 PECOS PAC ID: 6305994872 Enrollment ID: I20090511000577 |
News Archive
Metabolic syndrome in children represents a potentially serious threat to health in adulthood, yet many parents and caregivers do not have a clear idea of what metabolic syndrome is and why it is dangerous.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company's 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.
Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.
› Verified 3 days ago
| Provider Name | Nicole R Hazelwood |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1558504076 PECOS PAC ID: 4688726383 Enrollment ID: I20090709000776 |
News Archive
Metabolic syndrome in children represents a potentially serious threat to health in adulthood, yet many parents and caregivers do not have a clear idea of what metabolic syndrome is and why it is dangerous.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company's 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.
Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.
› Verified 3 days ago
| Provider Name | Darla K Pobst |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1184747545 PECOS PAC ID: 1951448042 Enrollment ID: I20091022000010 |
News Archive
Metabolic syndrome in children represents a potentially serious threat to health in adulthood, yet many parents and caregivers do not have a clear idea of what metabolic syndrome is and why it is dangerous.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company's 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.
Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.
› Verified 3 days ago
| Provider Name | Joseph K Essmyer |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1598841876 PECOS PAC ID: 6406015338 Enrollment ID: I20120312000697 |
News Archive
Metabolic syndrome in children represents a potentially serious threat to health in adulthood, yet many parents and caregivers do not have a clear idea of what metabolic syndrome is and why it is dangerous.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company's 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.
Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.
› Verified 3 days ago
| Provider Name | Tong Zhu |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1184853152 PECOS PAC ID: 8022243740 Enrollment ID: I20151027001616 |
News Archive
Metabolic syndrome in children represents a potentially serious threat to health in adulthood, yet many parents and caregivers do not have a clear idea of what metabolic syndrome is and why it is dangerous.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company's 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.
Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.
› Verified 3 days ago
News Archive
Metabolic syndrome in children represents a potentially serious threat to health in adulthood, yet many parents and caregivers do not have a clear idea of what metabolic syndrome is and why it is dangerous.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company's 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.
Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.
› Verified 3 days ago
Johns Healthcare Services Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2001 Independence St Ste A, Cape Girardeau, MO 63703 Phone: 573-304-3143 Fax: 573-334-0493 | |
Cross Trails Medical Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2430 Golden Street, Cape Girardeau, MO 63703 Phone: 573-339-1196 Fax: 573-339-9378 | |
Auburn Surgery Center Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 300 S Mount Auburn Rd, Ste 200, Cape Girardeau, MO 63703 Phone: 573-332-7881 Fax: 573-651-4431 | |
Midtown Family Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 24 N Sprigg St, Cape Girardeau, MO 63701 Phone: 573-332-7992 Fax: 573-332-7998 | |
Kenneth A Decoursey, Md Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1723 Broadway St, Suite 120, Cape Girardeau, MO 63701 Phone: 573-334-7194 Fax: 573-334-4937 | |
Immediate Healthcare, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1702 N Kingshighway St, Cape Girardeau, MO 63701 Phone: 573-339-2000 Fax: 573-339-1876 | |
Immediate Convenient Care Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1702 N Kingshighway St, Cape Girardeau, MO 63701 Phone: 573-339-2000 |